The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy
Open accessAbstract
PURPOSE: Heavy-metal chelators and inorganic nanoparticles (NPs) have been examined as potential radioenhancers to increase the efficacy of external beam radiation therapy for various cancers. Most of these agents have, unfortunately, displayed relatively poor pharmacokinetic properties, which limit the percentage of injected dose (%ID/g) that localizes to tumors and which shorten the window for effective radiation enhancement due to rapid tumor washout. METHODS AND MATERIALS: To address these challenges, we sought to conjugate gadolinium-based ultrasmall (<5 nm) NPs to an antibody directed against the oncogenic MUC1-C subunit that is overexpressed on the surface of many different human cancer types. The binding of the anti-MUC1-C antibody 3D1 to MUC1-C on the surface of a cancer cell is associated with its internalization and, thereby, to effective intracellular delivery of the antibody-associated payload, promoting its effective tumor retention. As such, we examined whether systemically administered anti-MUC1-C antibody-conjugated, gadolinium-based NPs (anti-MUC1-C/NPs) could accumulate within cell-line xenograft models of MUC1-C-expressing (H460) lung and (E0771) breast cancers to improve the efficacy of radiation therapy (XRT). RESULTS: The %ID/g of anti-MUC1-C/NPs that accumulated within tumors was found to be similar to that of their unconjugated counterparts (6.6 ± 1.4 vs 5.9 ± 1.7 %ID/g, respectively). Importantly, the anti-MUC1-C/NPs demonstrated prolonged retention in in vivo tumor microenvironments; as a result, the radiation boost was maintained during the course of fractionated therapy (3 × 5.2 Gy). We found that by administering anti-MUC1-C/NPs with XRT, it was possible to significantly augment tumor growth inhibition and to prolong the animals' overall survival (46.2 ± 3.1 days) compared with the administration of control NPs with XRT (31.1 ± 2.4 days) or with XRT alone (27.3 ± 1.6 days; P < .01, log-rank). CONCLUSIONS: These findings suggest that anti-MUC1-C/NPs could be used to enhance the effectiveness of radiation therapy and potentially to improve clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
As the field evolved, increasing emphasis was placed on functional modifications, including surface coatings, targeting ligands, biomimetic components, and therapeutic payloads, giving rise to multifunctional nanoplatforms capable of improving cellular uptake and integrating biological mechanisms of radiosensitization.
“As the field evolved, increasing emphasis was placed on functional modifications, including surface coatings, targeting ligands, biomimetic components, and therapeutic payloads, giving rise to multifunctional nanoplatforms capable of improving cellular uptake and integrating biological mechanisms of radiosensitization [24,27,29,55,66].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [66]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nanoparticle Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy
Kunjachan, S., Detappe, A., Kumar, R., Ireland, T. J., Cameron, L., Biancur, D. E., Motto‐Ros, V., Sancey, L., Sridhar, S., Makrigiorgos, G. M., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03073 · Cited by 153
Self-citationRetractedThe use of gold nanoparticles to enhance radiotherapy in mice
Hainfeld, J. F., Slatkin, D. N., & Smilowitz, H. M. (2004) · Physics in Medicine and Biology · doi:10.1088/0031-9155/49/18/n03 · Cited by 1,644
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,457
Mucins in cancer: function, prognosis and therapy
Kufe, D. W. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2761 · Cited by 1,433
Self-citationMUC1: a multifaceted oncoprotein with a key role in cancer progression
Nath, S., & Mukherjee, P. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.02.007 · Cited by 865
Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M., Ágoston, P., Hong, A., Mervoyer, A., Rastrelli, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30326-2 · Cited by 541
Physical basis and biological mechanisms of gold nanoparticle radiosensitization
Butterworth, K. T., McMahon, S. J., Currell, F. J., & Prise, K. M. (2012) · Nanoscale · doi:10.1039/c2nr31227a · Cited by 507
Kufe, D. W. (2012) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 452
Self-citationBiological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles
McMahon, S. J., Hyland, W. B., Muir, M. F., Coulter, J. A., Jain, S., Butterworth, K. T., Schettino, G., Dickson, G. R., Hounsell, A. R., O’Sullivan, J. M., et al. (2011) · Scientific Reports · doi:10.1038/srep00018 · Cited by 429
Nanoparticles for Radiation Therapy Enhancement: the Key Parameters
Retif, P., Pinel, S., Toussaint, M., Frochot, C., Chouikrat, R., Bastogne, T., & Barberi‐Heyob, M. (2015) · Theranostics · doi:10.7150/thno.11642 · Cited by 383
Haun, J. B., Devaraj, N. K., Hilderbrand, S. A., Lee, H., & Weissleder, R. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.148 · Cited by 348
Liu, Y., Zhang, P., Li, F., Jin, X., Li, J., Chen, W., & Li, Q. (2018) · Theranostics · doi:10.7150/thno.22172 · Cited by 335
Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization
Schuemann, J., Berbeco, R. I., Chithrani, D. B., Cho, S. H., Kumar, R., McMahon, S. J., Sridhar, S., & Krishnan, S. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.09.032 · Cited by 258
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Maeda, T., Hiraki, M., Jin, C., Rajabi, H. N., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1636 · Cited by 255
Self-citationThe use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy
Sancey, L., Lux, F., Kotb, S., Roux, S., Dufort, S., Bianchi, A., Crémillieux, Y., Fries, P., Coll, J., Rodriguez‐Lafrasse, C., et al. (2014) · British Journal of Radiology · doi:10.1259/bjr.20140134 · Cited by 245
Self-citationBonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1297 · Cited by 243
Deng, J., Xu, S., Hu, W., Xun, X., Zheng, L., & Su, M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.048 · Cited by 234
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
He, Y. J., Meghani, K. A., Caron, M., Yang, C., Ronato, D. A., Bian, J., Sharma, A., Moore, J. L., Joshi, N., Detappe, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0670-5 · Cited by 220
Self-citationEngineered gadolinium-doped carbon dots for magnetic resonance imaging-guided radiotherapy of tumors
Du, F., Zhang, L., Zhang, L., Zhang, M., Gong, A., Tan, Y., Miao, J., Gong, Y., Sun, M., Ju, H., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.008 · Cited by 206
Lux, F., Tran, V. L., Thomas, E., Dufort, S., Rossetti, F., Martini, M., Truillet, C., Doussineau, T., Bort, G., Denat, F., et al. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180365 · Cited by 189
Self-citationDetappe, A., Thomas, E., Tibbitt, M. W., Kunjachan, S., Zavidij, O., Parnandi, N., Reznichenko, E., Lux, F., Tillement, O., & Berbeco, R. I. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b05055 · Cited by 146
Self-citationVerry, C., Sancey, L., Dufort, S., Duc, G. L., Mendoza, C., Lux, F., Grand, S., Arnaud, J., Quesada, J. L., Villa, J., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023591 · Cited by 141
Self-citationBort, G., Lux, F., Dufort, S., Crémillieux, Y., Verry, C., & Tillement, O. (2020) · Theranostics · doi:10.7150/thno.37543 · Cited by 138
Self-citationTIRR regulates 53BP1 by masking its histone methyl-lysine binding function
Drané, P., Brault, M. E., Cui, G., Meghani, K. A., Chaubey, S., Detappe, A., Parnandi, N., He, Y. J., Zheng, X.-F., Botuyan, M. V., et al. (2017) · Nature · doi:10.1038/nature21358 · Cited by 136
Self-citationFunctional targeting of the MUC1 oncogene in human cancers
Kufe, D. W. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.13.8844 · Cited by 120
Self-citationChattopadhyay, N., Fonge, H., Cai, Z., Scollard, D. A., Lechtman, E., Done, S. J., Pignol, J., & Reilly, R. M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300016p · Cited by 115
Hafnium-doped hydroxyapatite nanoparticles with ionizing radiation for lung cancer treatment
Chen, M., Hanagata, N., Ikoma, T., Huang, J.-Y., Li, K.-Y., Lin, C., & Lin, F. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.04.004 · Cited by 111
Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells
Minafra, L., Porcino, N., Bravatà, V., Gaglio, D., Bonanomi, M., Amore, E., Cammarata, F. P., Russo, G., Militello, C., Savoca, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47553-2 · Cited by 108
The evolving genomic classification of lung cancer
Shames, D. S., & Wistuba, I. I. (2013) · The Journal of Pathology · doi:10.1002/path.4275 · Cited by 107
Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy
Detappe, A., Kunjachan, S., Sancey, L., Motto‐Ros, V., Biancur, D. E., Drané, P., Guièze, R., Makrigiorgos, G. M., Tillement, O., Langer, R., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.021 · Cited by 96
Self-citationAGuIX nanoparticles as a promising platform for image-guided radiation therapy
Detappe, A., Kunjachan, S., Rottmann, J., Robar, J. L., Tsiamas, P., Korideck, H., Tillement, O., & Berbeco, R. I. (2015) · Cancer Nanotechnology · doi:10.1186/s12645-015-0012-3 · Cited by 88
Self-citationTargeting the human MUC1-C oncoprotein with an antibody-drug conjugate
Panchamoorthy, G., Jin, C., Raina, D. B., Bharti, A. K., Yamamoto, M., Adeebge, D., Zhao, Q., Bronson, R. T., Jiang, S., Li, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99880 · Cited by 74
Self-citationMUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
Kharbanda, A., Rajabi, H. N., Jin, C., Alam, M., Wong, K., & Kufe, D. W. (2014) · Oncotarget · doi:10.18632/oncotarget.2360 · Cited by 67
Self-citationHainfeld, J. F., Ridwan, S. M., Stanishevskiy, Y. M., Panchal, R., Slatkin, D. N., & Smilowitz, H. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-41174-5 · Cited by 36
Detappe, A., Tsiamas, P., Ngwa, W. F., Zygmanski, P., Makrigiorgos, M. G., & Berbeco, R. I. (2013) · Medical Physics · doi:10.1118/1.4791671 · Cited by 35
Self-citationKey clinical beam parameters for nanoparticle-mediated radiation dose amplification
Detappe, A., Kunjachan, S., Drané, P., Kotb, S., Myronakis, M. E., Biancur, D. E., Ireland, T. J., Wagar, M., Lux, F., Tillement, O., et al. (2016) · Scientific Reports · doi:10.1038/srep34040 · Cited by 35
Self-citationDetappe, A., Reidy, M., Yu, Y., Mathieu, C., Nguyen, H. V. ‐., Coroller, T. P., Lam, F. C., Jarolı́m, P., Harvey, P., Protti, A., et al. (2019) · Nanoscale · doi:10.1039/c9nr06512a · Cited by 34
Self-citationBerbeco, R. I., Detappe, A., Tsiamas, P., Parsons, D. D. M., Yewondwossen, M., & Robar, J. L. (2015) · Medical Physics · doi:10.1118/1.4938410 · Cited by 23
Self-citationHofmann, C. L., O’Sullivan, M. C., Detappe, A., Yu, Y., Yang, X., Qi, W., Landon, C. D., Therien, M. J., Dewhirst, M. W., Ghoroghchian, P. P., et al. (2017) · Nanoscale · doi:10.1039/c7nr02363d · Cited by 16
Self-citationTran, V., Thakare, V., Natuzzi, M., Moreau, M., Oudot, A., Vrigneaud, J., Courteau, A., Louis, C., Roux, S., Boschetti, F., et al. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/7938267 · Cited by 10
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
MUC1: Structure, Function, and Clinic Application in Epithelial Cancers
Chen, W., Zhang, Z., Zhang, S., Zhu, P., Ko, J. K.-S., & Yung, K. K. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126567 · Cited by 248
Meta-Analysis of Nanoparticle Distribution in Tumors and Major Organs in Tumor-Bearing Mice
Chen, Q., Yuan, L., Chou, W., Cheng, Y., He, C., Monteiro-Riviere, N. A., Riviere, J. E., & Lin, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c04037 · Cited by 132
Wathoni, N., Puluhulawa, L. E., Joni, I. M., Muchtaridi, M., Mohammed, A. F. A., Elamin, K. M., Milanda, T., & Gozali, D. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2120566 · Cited by 111
Antibody‐Incorporated Nanomedicines for Cancer Therapy
Wu, S., Wu, F., & Chen, X. S. (2022) · Advanced Materials · doi:10.1002/adma.202109210 · Cited by 94
Zhao, F. Q., Tian, H., Wang, Y., Zhang, J., Liu, F., & Fu, L. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03364-5 · Cited by 38
Nanoparticles for MRI-guided radiation therapy: a review
Smith, L., Byrne, H. L., Waddington, D. E. J., & Kuncic, Z. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00145-8 · Cited by 37
Nanoparticle Targeting with Antibodies in the Central Nervous System
Lee, J.-H., Chapman, D. V., & Saltzman, W. M. (2023) · BME Frontiers · doi:10.34133/bmef.0012 · Cited by 36
Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy
Tong, X., Dong, C., & Liang, S. (2023) · Journal of Cancer · doi:10.7150/jca.88261 · Cited by 27
Yu, B., Lu, X., Feng, X., Zhao, T., Li, J., Lu, Y., Ye, F., Liu, X., Zheng, X., Shen, Z., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s428044 · Cited by 23
Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review
Aubrun, C., Doussineau, T., Carmès, L., Meyzaud, A., Boux, F., Dufort, S., Delfour, A., de Beaumont, O., Mirjolet, C., & Duc, G. L. (2025) · Pharmaceuticals · doi:10.3390/ph18040519 · Cited by 19
The multifaceted role of MUC1 in tumor therapy resistance
Jin, W., Zhang, M., Dong, C., Huang, L. H., & Luo, Q. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00978-y · Cited by 17
Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma
Thomas, E., Mathieu, C., Moreno‐Gaona, P., Mittelheisser, V., Lux, F., Tillement, O., Pivot, X. B., Ghoroghchian, P. P., & Detappe, A. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101565 · Cited by 13
Self-citationMUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells
Daimon, T., Bhattacharya, A., Wang, K., Haratake, N., Nakashoji, A., Ozawa, H., Morimoto, Y., Yamashita, N., Kosaka, T., Oya, M., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01772-9 · Cited by 12
Self-citationAGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors
Carmès, L., Bort, G., Lux, F., Seban, L., Rocchi, P., Muradova, Z., Hagège, A., Heinrich, L., Delolme, F., Gueguen‐Chaignon, V., et al. (2023) · Nanoscale · doi:10.1039/d3nr04777f · Cited by 12
Self-citationMelatonin Modulation of Radiation-Induced Molecular Changes in MCF-7 Human Breast Cancer Cells
Alonso‐González, C., González-Abalde, C., Menéndez-Menéndez, J., González-González, A., Garcia, V. A., González-Cabeza, A., Martínez‐Campa, C., & Cos, S. (2022) · Biomedicines · doi:10.3390/biomedicines10051088 · Cited by 11
Toward Clinical Transfer of Tumor‐Targeted Ultrasmall Inorganic Nanoparticles
Carmès, L., Banerjee, M., Coliat, P., Harlepp, S., Pivot, X. B., Tillement, O., Lux, F., & Detappe, A. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300019 · Cited by 10
Self-citationApplication of nano-radiosensitizers in non-small cell lung cancer
Hu, X., Hu, J., Pang, Y., Wang, M., Zhou, W., Xie, X., Zhu, C., Wang, X., & Sun, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1372780 · Cited by 8
Erickson, A., Jackson, L. R., Camphausen, K. A., & Krauze, A. V. (2024) · Biomedicines · doi:10.3390/biomedicines12122806 · Cited by 5
Realizing active targeting in cancer nanomedicine with ultrasmall nanoparticles
Lima, A. F., Justo, G. Z., & Sousa, A. A. (2024) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.15.98 · Cited by 4
Yuan, Q., Cai, S., Chang, Y., Zhang, J., Wang, M., Yang, K., & Jiang, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608140 · Cited by 3
Lunca, S., Morarasu, S., & Dimofte, G. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146522 · Cited by 2
“…was placed on functional modifications, including surface coatings, targeting ligands, biomimetic components, and therapeutic payloads, giving rise to multifunctional nanoplatforms capable of improving cellular uptake and integrating biological mechanisms of radiosensitization [24,27,29,55,66].”
MUC1 in the upper–lower airway inflammatory continuum: an endotype-centered perspective
Meng, L., Liu, J., Ong, H. H., Wang, D. Y., & Shi, L. (2025) · Inflammation Research · doi:10.1007/s00011-025-02110-8 · Cited by 2
Qian, K., Zhang, Y., Zhou, Q., 周建明, Wu, X., Zhu, J., Pan, Y. P., Wu, Z., Li, S., Lin, Y., et al. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-026-00257-w · Cited by 2
Mi, K., Chen, Q., Viswanathan, S., Santhosh, I. J., Quazi, H., He, C., Monteiro-Riviere, N. A., Riviere, J. E., Aryal, S., & Lin, Z. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.101017 · Cited by 1
Wang, Z., Lu, R., Jiang, M., Chu, X., & Zhou, R. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4790904
Mittelheisser, V. (2024) · theses.fr (ABES) · doi:10.70675/92b9630bz16afz4843z93caz705680f2ac69
Raj, A., Chattopadhyay, S., Alex, A. T., Mutalik, S., Kundoolithodi, R., Ellyan, N. S., & Sarath Chandran, C. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108630
Metadata
- Authors
- Detappe, A., Mathieu, C., Jin, C., Agius, M. P., Diringer, M.-C., Tran, V.-L., Pivot, X., Lux, F., Tillement, O., Kufe, D., & Ghoroghchian, P. P.
- Affiliations
- Harvard University (US)
- Institut Strauss (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Detappe, Alexandre
- ORCID
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 108
- Issue
- 5
- Pages
- 1380-1389
- ISSN
- 0360-3016 (ISSN-L)
- PMC
- PMC7680267
- OpenAlex
- W3038416231
- Cited by
- 27
- References
- 40
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 2
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Radiation Oncology*Biology*Physics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, cc-by-nc)
- Funders
- National Cancer Institute
- Topics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- MUC1-C, antibody-conjugated nanoparticles, gadolinium nanoparticles, fractionated radiotherapy, tumor retention, targeted drug delivery, lung cancer, breast cancer, xenograft models, tumor growth inhibition, overall survival
- MeSH terms
- Animals, Antibodies, Monoclonal, DNA Damage, Female, Gadolinium, Humans, Immunologic Factors, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mucin-1, Immunoconjugates, Dose Fractionation, Radiation, Cell Line, Tumor, Mice, Nanoparticles, Tumor Microenvironment, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
